ArticleDiscover oncology2026
Genetic influence of PPAR-γ rs1801282 and MTRR rs162036 variants on non-small cell lung cancer risk in Egyptians.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer remains the leading cause of cancer-related deaths worldwide. Despite advances in diagnostics and treatment, most patients are diagnosed at advanced stages. Genetic variants such as single nucleotide polymorphisms (SNPs) may improve early detection and risk prediction. This study investigated the association of PPAR-γ rs1801282 and MTRR rs162036 polymorphisms with non-small cell lung cancer (NSCLC) susceptibility in Egyptians and further evaluated their role through a meta-analysis.
methodsA case-control study was conducted including 127 NSCLC patients and 138 age- and sex-matched healthy controls. Genotyping of PPAR-γ rs1801282 and MTRR rs162036 variants was performed using the T-ARMS-PCR method. Logistic regression, stratified and multivariate analyses, and bioinformatics approaches were applied to assess genetic associations. In addition, a meta-analysis of previously published studies was performed to evaluate the overall association of these polymorphisms with cancer risk.
resultsThe PPAR-γ rs1801282 C>G variant showed a significant association with NSCLC risk in both the dominant (adjusted OR = 6.74, p < 0.001) and allelic models (adjusted OR = 6.10, p = 0.001). Stratified analysis indicated higher susceptibility among males, older individuals, and nonsmokers. No significant association was observed for the MTRR rs162036 variant (p > 0.05). The meta-analysis findings were consistent with the overall lack of association between MTRR rs162036 and cancer risk, while supporting a potential role for PPAR-γ rs1801282 in cancer susceptibility.
conclusionsThe PPAR-γ rs1801282 polymorphism may serve as a potential genetic marker for NSCLC risk in Egyptians, whereas MTRR rs162036 shows no significant impact. The combined evidence from the case-control study and meta-analysis highlights the importance of population-specific genetic investigations in NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.